Aquestive Therapeutics Faces Securities Fraud Lawsuit as Shares Drop Over 37%
Aquestive Therapeutics (AQST) is facing a securities fraud lawsuit, with shares dropping over 37% following allegations of misleading statements about the regulatory approval timeline for its product Anaphylm. Institutional investors holding shares between June 16, 2025, and January 8, 2026, may seek to lead the class action, with a deadline set for May 4, 2026.
Tickers: $AQST
Topics: class action lead plaintiff appointment regulatory approval securities litigation stock price decline